Evidence map›Paper›PMID 42621701›Full record

ArticleCancer research2026

Mathematical and Mouse Models Identify Regulatory T Cell Influx as A Key Determinant of Acquired Resistance to PD-1 Immunotherapy.

Rachel S Sousa, Shannon N Geels, Claire Murat, Alexander Moshensky, Mauro Di Pilato, S Armando Villalta, John S Lowengrub, Francesco Marangoni

Abstract read
In one paragraph

Article in Cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Rachel S SousaUniversity of California, Irvine Irvine United States.ORCID 0009-0003-0896-6926
Shannon N GeelsUniversity of California, Irvine Irvine United States.ORCID 0000-0002-7991-6104
Claire MuratUniversity of California, Irvine Irvine, CA United States.ORCID 0000-0003-2359-6444
Alexander MoshenskyUniversity of California, Irvine Irvine United States.ORCID 0000-0002-1778-4601
Mauro Di PilatoThe University of Texas MD Anderson Cancer Center Texas United States.ORCID 0000-0003-3902-7406
S Armando VillaltaUniversity of California, Irvine Irvine United States.ORCID 0000-0002-5212-2259
John S LowengrubUniversity of California, Irvine Irvine United States.ORCID 0000-0003-1759-0900
Francesco MarangoniUniversity of California, Irvine Irvine, CA United States.ORCID 0000-0002-2490-849X

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
Understanding critical transitions in chronic myeloid leukemia to improve tyrosine kinase inhibitor therapyP01CA288662 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Anand K Ganesan · 2025 to 2026
$6.4M
Novel macrophage and regulatory T cell interactions that promote the pathogenesis of Duchenne muscular dystrophyR01NS120060 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI VILLALTA, SERGIO ARMANDO · 2020 to 2024
$2.5M
Immunology Research Training GrantT32AI177324 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI Eric Pearlman · 2023 to 2026
$735k
Mechanisms of immunosuppression triggered by checkpoint blockade immunotherapyR01CA287116 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Francesco Marangoni · 2026 to 2026
$649k
Disentangling the Epidermal Immune Crosstalk in Inflammatory Skin DiseaseF31AR083279 · NIAMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI MOSHENSKY, ALEXANDER · 2023 to 2025
$136k
NCI NIH HHS P01 CA288662NCI NIH HHS P30 CA062203NCI NIH HHS R01 CA287116NIAID NIH HHS T32 AI177324NIAMS NIH HHS F31 AR083279NINDS NIH HHS R01 NS120060
6 · The paper itself

Abstract

The immune system can eradicate cancer, but various immunosuppressive mechanisms active within a tumor curb this beneficial response. However, unraveling the effects of multimodal interactions between tumor and immune cells and their contributions to tumor control using an experimental approach alone is time- and resource-intensive. To identify the critical immunological features associated with tumor control and escape, we built a mechanistic, structurally identifiable mathematical model of the interactions between CD8+ T cells, regulatory T cells (Tregs), dendritic cells, and tumor cells deeply rooted in current biological concepts. The model captured Treg accrual occurring after checkpoint blockade immunotherapy. After successfully fitting the mathematical model to experimental data from an immunogenic melanoma mouse model with acquired resistance to PD-1 immunotherapy and ensuring that the model was practically identifiable, hundreds of parameter sets were generated, each of which fit the data well and represented a unique 'virtual mouse' to capture variability across individuals. The model indicated that the initial tumor and immune conditions instruct cancer control or progression and that optimal initial ratios of immune cells exist that result in improved tumor control. The model further predicted that the Treg influx into the tumor is a key determinant of resistance to PD-1 immunotherapy. Experimental studies validated all these predictions from the model. Overall, this integrated approach of modeling and experimental validation identified crucial determinants of resistance to PD-1 immunotherapy and can be used to guide the development of more effective therapeutic strategies.

Identifiers

PMID42621701
PMCPMC13614702

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.